Biogen (BIIB) PT Raised to $300 at Wedbush, After FDA Approves Aduhelm (Aducanumab)
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $195.96 +3.78%
Rating Summary:
25 Buy, 18 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
25 Buy, 18 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $240.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Shiseido Co Ltd. (4911:JP) (SSDOY) PT Lowered to JPY2,750 at Nomura/Instinet
- Nomura/Instinet Downgrades T&D Holdings Inc (8795:JP) (TDHOY) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
